Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia
A Systematic Review and Meta-Analysis
Bibliographic Data
| ID | 21748722 |
|---|---|
| Authors | Tong Cai (0000-0001-9416-5508, Binzhou Medical University, Yantai, Shandong, China), Zhongbao Zhou (0000-0002-9810-8145, Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China), Shaoxia Yu (Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China), Qian Li (0000-0003-1286-8539, Department of Research, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China), Zhenli Gao (Binzhou Medical University, Yantai, Shandong, China) |
| Year | 2020 |
| Volume | 14 |
| Issue | 2 |
| Publication date | 2020-03-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | American Journal of Men s Health (JOURNAL) |
| Journal identifiers | ISSN: 1557-9883 • E-ISSN: 1557-9891 |
| Publisher | SAGE Publications (PUBLISHER • US) |
| DOI | 10.1177/1557988320905407 |
| Language | EN |
| Citations received | 1 |
| References cited | 36 |
Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms (LUTS). This article carried out a systematic review and meta-analysis to compare Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia (BPH) after at least 6-month treatment cycle. Four studies involving 1,080 patients (543 in the Serenoa repens group and 537 in the tamsulosin group) were included in the meta-analysis. The results were as follows: compared with tamsulosin, Serenoa repens had a same effect in treating BPH in terms of International Prostate Symptom Score (IPSS) (mean difference [MD] 0.63, 95% confidence interval [CI] [−0.33, 1.59], p = 0.20), quality of life (QoL) (MD 1.51, 95% CI [−1.51, 4.52], p = 0.33), maximum flow rate (Qmax) (MD 0.27, 95% CI [−0.15, 0.68], p = 0.21), postvoid residual volume (PVR) (MD −4.23, 95% CI [−22.97, 14.44], p = 0.65), prostate-specific antigen (PSA) (MD 0.46, 95% CI [−0.06, 0.97], p = 0.08) with the exception of prostate volume (PV) (MD −0.29, 95% CI [−0.41, −0.17], p
| Unique citing works | 1 |
|---|---|
| Citations per year | 0,17 |
| Citation span | 2020 - 2020 (1) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 1 |